Cancer-related anaemia
Journal Title: Współczesna Onkologia - Year 2006, Vol 10, Issue 6
Abstract
Cancer-related anaemia occurs during the underlying malignancy in 40-75 percent of the patients. It has the influence on the quality of life, which can be significantly reduced and on the results of the planned and undergoing treatment. The mild anaemia can negatively impact the therapeutic treatment. Anaemia is often exacerbated by cancer treatment- -chemotherapy and radiotherapy. The blood transfusions or erythropoietin therapy help to equalize the decreased level of haemoglobin. Particular attention must be paid to the patients who received myelosuppressive treatment, radiation (in the pelvis minor area) and in cases when after the first course of chemotherapy the level of haemoglobin decreased by 2 g/dl. Numerous clinical studies have shown that erythropoietin can be an effective treatment in cancer-related anaemia.
Authors and Affiliations
Krzysztof Gawrychowski
Keywords
Related Articles
- EP ID EP154626
- DOI -
- Views 67
- Downloads 0
Centralny ziarniniak olbrzymiokomórkowy żuchwy o różnym przebiegu klinicznym – przegląd piśmiennictwa i własne obserwacje
Centralny ziarniniak olbrzymiokomórkowy (Central Giant Cell Granuloma, CGCG) należy – wg klasyfikacji WHO – do zmian guzopodobnych. Jest to rzadko występująca zmiana odczynowa w obrębie części twarzowej czaszki (7%), z...
Clinical utility of complementary measurements standard tumor markers and cytokines in patients with cervical cancer
We aimed to relate the levels of serum tumour markers (CEA, CA 125, CYFRA 21.1) and cytokines (IL-6, VEGF) in cervical cancer patients to the clinicopathologic features of the disease and to estimate the value of these...
Primary malignant neoplasms of the tongue
Malignant neoplasms of the tongue are relatively common. Squamous cell carcinoma accounts for approximately 95% of malignant neoplasms in maxillofacial region. Carcinomas of the tongue make up about 40% of all malignant...
\"Novus ordo seclorum\": new applications af monoclonal antibodies in breast cancer
Trastuzumab (Herceptin) is a recombinant humanized monoclonal IgG1 antibody inhibiting selectively HER2 receptor in tumour cells, that has found a clinical application in breast cancer treatment. Until recently, this com...
Cancer-related anaemia
Cancer-related anaemia occurs during the underlying malignancy in 40-75 percent of the patients. It has the influence on the quality of life, which can be significantly reduced and on the results of the planned and und...